Mike Evers, Author at ORTHOWORLD

Orthopedic M&A Punches Above Its Weight Class

Orthopedic M&A is more active and has higher multiples than general medtech, but economic conditions will limit growth for now.

Dec 05, 2023

In this brief video we look at key performance metrics for the orthopedic market in 2023 and expected market forces for 2024.

Nov 28, 2023

Stay up to date on the orthopedic market's 3Q performance in 2023 as we update this post with company sales data and industry developments.

Nov 28, 2023

Our chart of the month tracks DePuy Synthes’ sales by business unit from 2016 through our 2023 projection.

Nov 20, 2023

We spoke with Anika President and CEO Cheryl Blanchard, Ph.D. about the RevoMotion launch, ASCs, and robotics in the shoulder market.

Nov 20, 2023

The company grew in the mid-teens in 3Q23 and sees competitors putting less focus on treating pediatric trauma and deformity.

Nov 15, 2023

The company notched its fifth consecutive quarter with more than 20% growth and is on track for arthroscopic MACI delivery in 1H24.

Nov 15, 2023

The company grew 61% as-reported in the third quarter of 2023, or 1.2% on a pro forma basis including prior year SeaSpine sales.

Nov 14, 2023

The company grew in the mid-teens during the third quarter of 2022, driven by sales force and active surgeon base growth.

Nov 14, 2023

The company grew more than 23% in 3Q23 but ultimately reduced its guidance because of higher-than-expected seasonality during the summer.

Nov 14, 2023